# Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

> **NCT05183048** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 14 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** [89Zr]Panitumumab Tracer

## Key facts

- **NCT ID:** NCT05183048
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-20
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183048, "Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05183048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*